| February 2 |
Pfizer Discontinues Global Phase III Trial of Axitinib for Futility in Advanced Pancreatic Cancer |
| February 2 |
Aastrom Phase II IMPACT-DCM Trial Placed On Clinical Hold Pending Review of Isolated Serious Adverse Event |
| February 2 |
Federal Trade Commission Files Complaint Against Par Pharmaceutical Over Court-Approved AndroGel Litigation Settlement |
| February 2 |
Hollis-Eden Pharmaceuticals Announces Cost-Cutting Measures to Focus Resources on Advancement of Ongoing Clinical Development Programs |
| February 3 |
Schering-Plough Reports Financial Results for 2008 Fourth Quarter, Full Year |
| February 3 |
Merck Announces Fourth-Quarter and Full-Year 2008 Financial Results |
| February 3 |
King Pharmaceuticals Announces Corporate Restructuring to Reduce Operating Expenses |
| February 3 |
PharmaNet Development Group Agrees to be Acquired by JLL Partners |
| February 3 |
Astellas Announces Global Development Organizational Changes |
| February 4 |
Allergan Reports Fourth Quarter 2008 Operating Results and Announces Restructuring |
| February 4 |
Early Communication about an Ongoing Safety Review Xigris (Drotrecogin alfa [activated]) |
| February 4 |
What's the ideal relationship between the drug industry, health professionals and patients? |
| February 4 |
Sens. Kohl, Grassley Introduce Bill to Stop Industry 'Payoffs' That Delay Generic Drugs |
| February 4 |
University of Maryland School of Medicine and Medical Center Implement New Policies Governing Physician/Industry Relationships |
| February 4 |
Strong operating results for Roche in 2008 |
| February 5 |
GSK Delivers EPS of 104.7p Before Major Restructuring |
| February 5 |
Breast Cancer Risk Rapidly Declines After Women Stop Taking Postmenopausal Combined Hormone Therapy |
| February 6 |
Vertex Pharmaceuticals Announces Transition in Company Leadership |
| February 6 |
Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899 for HIV |
| February 6 |
Biogen Idec Reports Full Year and Fourth Quarter 2008 Results |
| February 6 |
Biogen Idec Receives Shareholder Proposal |
| February 6 |
Avigen Board Rejects BVF Offer as Inadequate |
| February 6 |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and Invega |
| February 6 |
Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review |
| February 6 |
Future Pharmaceutical Innovation Requires Patients to be Placed Right at the Centre |
| February 6 |
Schering Plough Invests $30 Million in Scottish Facility |
| February 6 |
Taro Receives FDA Warning Letter Following Inspection of Its Canadian Manufacturing Facility |
| February 6 |
Sudler & Hennessey Expands Montreal Presence |
| February 9 |
H. Lundbeck A/S (DK) - Lundbeck to acquire US-based Ovation Pharmaceuticals, Inc. |
| February 9 |
KV Pharmaceutical Company Reduces Workforce |
| February 9 |
Dynavax Announces Receipt of Communication from the U.S. FDA on HEPLISAV Hepatitis B Vaccine |
| February 9 |
GTCR Announces Agreement to Sell Ovation Pharmaceuticals |
| February 9 |
Mass. AG Martha Coakley Enters Agreement with Bayer Corporation Resolving Allegations of Deceptive Advertising of Oral Contraceptive |
| February 10 |
FDA to Meet with Drug Companies about REMS for Certain Opioid Drugs |
| February 10 |
Pfizer to Publicly Disclose Payments to U.S. Physicians, Healthcare Professionals and Clinical Investigators |
| February 10 |
Genentech Urges Shareholders to Take No Action With Respect to Unsolicited Tender Offer From Roche |
| February 10 |
Roche Commences Tender Offer for Genentech for US$86.50 Per Share in Cash |
| February 10 |
New Guidelines for Prescribing Opioid Pain Drugs Published |
| February 10 |
FDA to Meet with Drug Companies about REMS for Certain Opioid Drugs |
| February 10 |
Enzon Discontinues Further Development of rhMBL |
| February 10 |
SK&A Study: More Docs Limit Sales Rep Access |
| February 10 |
Significant Shareholder Calls upon Enzon to Immediately Add Two Candidates to the Board of Directors |
| February 11 |
FDA and International Serious Adverse Events Consortium Release First Data on Genetic Basis of Adverse Drug Events |
| February 11 |
FDA Issues Complete Response Letter for Risperdal Consta for the Adjunctive Maintenance Treatment of Bipolar Disorder |
| February 11 |
FDA and Kaplan EduNeering expand alliance |
| February 11 |
Sanofi-aventis Delivers 2008 Results Above Guidance |
| February 11 |
Strong Fourth Quarter for Genzyme Concludes Productive Year |
| February 11 |
Bristol-Myers Squibb Statement on Mead Johnson Nutrition Company IPO |
| February 12 |
Bayer Schering Pharma to Invest 100 Million Euro in China to Build a Global R&D Center |
| February 12 |
Merck & Co., Inc. Acquires Biologic Manufacturing Capabilities and Developmental Follow-on Biologics Portfolio from Insmed |
| February 12 |
Pharmalive.com Launches Medical Device Industry Report |
| February 12 |
Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel |
| February 12 |
Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline |
| February 12 |
Oscient Pharmaceuticals Restructures Commercial Organization |
| February 13 |
Sandoz Receives European Commission Approval For Biosimilar Filgrastim |
| February 13 |
Haemacure Restructures - Seeks Financing or Sale of the Company |
| February 13 |
Clinicians Using Electronic Prescribing Override Most Medication Safety Alerts |
| February 13 |
Spending for Prescription Pain Medicines Has Tripled in 10 Years |
| February 13 |
Novogen to Focus on Oncology Program |
| February 13 |
ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients |
| February 17 |
FDA Approves ULORIC (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout |
| February 17 |
Hospira Reports Fourth-Quarter and Full-Year 2008 Results |
| February 17 |
Teva Reports Record Full Year 2008 and Fourth Quarter Results |
| February 17 |
Synta Earns $10 Million from GlaxoSmithKline for Achieving Elesclomol Milestone |
| February 17 |
Merck Sharp & Dohme Ltd Withdraws Its Marketing Authorisation Application For Vorinostat MSD (Vorinostat) |
| February 17 |
Doctors' Resources for Off-Label Prescribing May Be Incomplete, Unclear |
| February 17 |
Teva Provides 2009 Financial Outlook |
| February 18 |
CSL Limited announce Half-Year Results for 2008/09 |
| February 18 |
Merck KGaA: 2008 Operating Result Rises 16% to € 1,131 Million |
| February 18 |
Type of Rheumatoid Arthritis Medication May be Associated With Increased Risk for Shingles |
| February 18 |
GPC Biotech and Agennix Announce Proposed Merger |
| February 18 |
Cipher receives tentative FDA approval for extended-release tramadol capsules |
| February 18 |
Jury Finds Pharmacia Committed Fraud On Wisconsin Medicaid Program; Van Hollen’s Department Of Justice Wins State $9 Million |
| February 19 |
Shire Delivers Excellent Growth for the Year, with the New Product Portfolio Achieving Sales of $1 Billion |
| February 19 |
Solvay: 2008 Operating Result (EUR 965 Million) Down By 19% Compared To The Record Result of 2007 |
| February 19 |
Sanofi-Aventis U.S. Launches Diabetes-Focused YouTube Channel |
| February 19 |
European Commisssion Grants Ferring Pharmaceuticals Approval of Firmagon (Degarelix) for Treatment of Prostate Cancer |
| February 19 |
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva |
| February 19 |
FDA Public Health Advisory: Updated Safety Information about Raptiva (efalizumab) |
| February 19 |
United States Joins Suits Against Scios and Johnson & Johnson |
| February 19 |
European Medicines Agency recommends continued vaccination with Gardasil |
| February 19 |
European Medicines Agency recommends new contraindication and warning for Rasilez and other aliskiren medicines |
| February 19 |
Dallas Scientists Discover Statins May Falsely Indicate Thyroid Problems |
| February 19 |
La Jolla Pharmaceutical Company Announces Reduction in Workforce and Evaluates Strategic Options |
| February 20 |
CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results |
| February 20 |
CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal |
| February 20 |
Schering-Plough Submits Response to FDA for SAPHRIS (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder |
| February 20 |
UCB (BE) - UCB to Divest Equasym |
| February 20 |
Shire to Enter European ADHD Market With the Acquisition of Equasym IR and XL |
| February 20 |
Questions of Ethics and Quality Cloud Globalization of Clinical Trials |
| February 20 |
House Committee on Energy and Commerce Chairmen Waxman and Stupak Request Study Data for Vytorin |
| February 20 |
Daiichi Sankyo Notice on Organizational Restructuring as of April 1, 2009 |
| February 20 |
Discontinuation of Development of TAK-242 for Severe Sepsis |
| February 20 |
Shire Announces Opening of Office in Japan |
| February 20 |
Neuralstem's ALS Trial on Clinical Hold |
| February 23 |
Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics |
| February 23 |
Astellas Pharma Issues Statement Regarding CV Therapeutics Rejection of All-Cash Proposal |
| February 23 |
European Commission Approves EFIENT (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI |
| February 23 |
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression |
| February 23 |
Patient Knowledge of Health Information Influences Cancer Treatment |
| February 23 |
Two FDA Quality Systems Compliance Resources Published |
| February 23 |
MedWatch - Zonisamide (marketed as Zonegran, and generics) Can Cause Metabolic Acidosis in Some Patients |
| February 24 |
Genentech Announces March 2, 2009 Webcast of Investment Community Meeting |
| February 24 |
Genentech Special Committee Rejects Roche's $86.50 Offer as Inadequate |
| February 24 |
Panacos Provides Corporate and Strategic Update |
| February 24 |
AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints |
| February 24 |
Basilea Pharmaceutica Ltd. (CH) - Basilea Pharmaceutica Files Claims Against Johnson & Johnson Over Its Handling of Ceftobiprole (ZEFTERA/Zevtera) Clinical Studies |
| February 24 |
Basilea Pharmaceutica Ltd. (CH) - Zevtera Review Process Delayed in EU |
| February 24 |
Orion Corporation (FI) - Orion: Primary Objective of STRIDE-PD Study Was Not Achieved |
| February 24 |
Pfizer Discontinues Development of Two Phase 3 Compounds |
| February 24 |
US Physicians Sharply Increase Their Negative Word of Mouth about Pharma, with EU Doctors Also Expressing High Dissatisfaction |
| February 25 |
Elan Announces Further Alignment of Resources as Part of On-Going Strategic Review Process |
| February 25 |
Abbott Successfully Completes Tender Offer for Shares of Advanced Medical Optics |
| February 25 |
Smaller, Refocused Salesforce Will Enable Pharmaceutical Companies to Create Greater Value for Patients, Says New PricewaterhouseCoopers Report |
| February 25 |
Press Statement Issued by Ranbaxy Laboratories Limited |
| February 25 |
United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act |
| February 25 |
Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring |
| February 26 |
FDA Takes New Regulatory Action Against Ranbaxy’s Paonta Sahib Plant in India |
| February 26 |
Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government |
| February 26 |
King Pharmaceuticals Reports Year-End and Fourth-Quarter 2008 Financial Results |
| February 26 |
Parents Learn About HPV Vaccine Mostly from Drug Company Ads |
| February 27 |
Endo Pharmaceuticals Returns Product Rights to Transdur-Sufentanil to Durect |
| February 27 |
FDA Sends Letter to GlaxoSmithKline Over Avodart Ad |
| February 27 |
Synta Suspends Elesclomol SYMMETRYTrial in Metastatic Melanoma |
| February 27 |
FDA Requires Boxed Warning and Risk Mitigation Strategy for Metoclopramide-Containing Drugs |
| February 27 |
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease |
| February 27 |
Astellas Files Lawsuit Against CV Therapeutics |
